Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.

MLA

Roussel, Ronan, et al. “Use of Dipeptidyl Peptidase‐4 Inhibitors and Prognosis of COVID‐19 in Hospitalized Patients with Type 2 Diabetes: A Propensity Score Analysis from the CORONADO Study.” Diabetes, Obesity & Metabolism, vol. 23, no. 5, May 2021, pp. 1162–72. EBSCOhost, https://doi.org/10.1111/dom.14324.

APA

Roussel, R., Darmon, P., Pichelin, M., Goronflot, T., Abouleka, Y., Ait Bachir, L., Allix, I., Ancelle, D., Barraud, S., Bordier, L., Carlier, A., Chevalier, N., Coffin, B. C., Cosson, E., Dorange, A., Dupuy, O., Fontaine, P., Fremy, B., Galtier, F., & Germain, N. (2021). Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. Diabetes, Obesity & Metabolism, 23(5), 1162–1172. https://doi.org/10.1111/dom.14324

Chicago

Roussel, Ronan, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, et al. 2021. “Use of Dipeptidyl Peptidase‐4 Inhibitors and Prognosis of COVID‐19 in Hospitalized Patients with Type 2 Diabetes: A Propensity Score Analysis from the CORONADO Study.” Diabetes, Obesity & Metabolism 23 (5): 1162–72. doi:10.1111/dom.14324.